Role of 5 Alpha-Reductase Inhibitors in the Management of Prostate Cancer

The document reviewed the role of 5 alpha-reductase inhibitors, such as finasteride and dutasteride, in managing prostate cancer. These inhibitors were shown to reduce PSA levels and prostate volume, potentially delaying cancer progression. Clinical trials, including the Prostate Cancer Prevention Trial with 18,882 men, indicated a nearly 25% reduction in prostate cancer risk with finasteride, though concerns about high-grade cancer diagnoses were noted. Dutasteride also showed promise, with ongoing trials like REDUCE evaluating its efficacy. While these inhibitors were well-tolerated and showed some efficacy, definitive evidence of improved survival was lacking, necessitating further research to confirm their benefits and address safety concerns.